ReviewNature reviews. Urology2011
Estrogen and androgen signaling in the pathogenesis of BPH.
Review in Nature reviews. Urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- A scalable outpatient framework for BI-RADS 2-4B breast nodule management: an iodine-DMSO transdermal protocol.Frontiers in health services · 2026Pooled it
- The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.Medicine · 2016Pooled it
- Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men.The Journal of clinical endocrinology and metabolism · 2016Trial
- Article
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
- SRD5A2 and emerging therapies in androgen-driven disorders.Nature reviews. Urology · 2026Review
- Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR/TGF-β1/Smad2 axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Finasteride Use Does Not Lead to Depression or Suicide: Insights From a Large-Scale Cohort Study and Mendelian Randomization Analysis.Journal of cosmetic dermatology · 2025Article
- Pleiotrophin modulates cell proliferation, prostate smooth muscle contraction and fibrosis in hyperplastic prostate.Journal of translational medicine · 2025Article
- Impact of fatty liver index and metabolic dysfunction-associated steatotic liver disease on the risk of benign prostatic hyperplasia in older male adults.BMC geriatrics · 2025Article
- The combination of water extracts ofNutrition research and practice · 2025Article
- Exploring TGF-β signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications.Biogerontology · 2025Review
- Chewable tablets containing rape bee pollen and maca attenuate testosterone propionate-induced benign prostatic hyperplasia in Sprague-Dawley rats by regulating the gut microbiota and modulating the IL-6/JAK2/STAT3 signaling pathway.Frontiers in microbiology · 2025Article
- Article
- Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia.Chinese journal of integrative medicine · 2025Review
- Extracellular Vesicles in the Aging Male Reproductive System: Progresses and Perspectives.Advances in experimental medicine and biology · 2025Review
- Gut Microbiota Disorders in Obesity-Associated Benign Prostatic Hyperplasia in Rats.Biochemical genetics · 2024Article
- Circulating levels of blood biomarkers and risk of benign prostatic hyperplasia: Results from two large cohorts in Europe and East Asia.Journal of global health · 2024Article
- Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting β-catenin pathway.Molecular biomedicine · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogens and androgens have both been implicated as causes of benign prostatic hyperplasia (BPH). Although epidemiological data on an association between serum androgen concentrations and BPH are inconsistent, it is generally accepted that androgens play a permissive role in BPH pathogenesis. In clinical practice, inhibitors of 5α-reductase (which converts testosterone to the more potent androgen dihydrotestosterone) have proven effective in the management of BPH, confirming an essential role for androgens in BPH pathophysiology. To date, multiple lines of evidence support a role for estrogens in BPH pathogenesis. Studies of the two estrogen receptor (ER) subtypes have shed light on their differential functions in the human prostate; ERα and ERβ have proliferative and antiproliferative effects on prostate cells, respectively. Effects of estrogens on the prostate are associated with multiple mechanisms including apoptosis, aromatase expression and paracrine regulation via prostaglandin E2. Selective estrogen receptor modulators or other agents that can influence intraprostatic estrogen levels might conceivably be potential therapeutic targets for the treatment of BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.